Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.254
Sell
RSI(14)
40.668
Neutral
STOCH(KDJ)(9,3,3)
21.838
Neutral
ATR(14)
1.198
High Vlolatility
CCI(14)
-157.375
Sell
Williams %R
71.779
Sell
TRIX(12,20)
-0.661
Sell
StochRSI(14)
51.683
Buy
Avalo Therapeutics Inc
AVTX14.190USD
+1.040+7.91%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
252.97MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Avalo Therapeutics Inc
Currency: USD Updated: 2026-02-06Key Insights
Avalo Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 178 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 36.11.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Avalo Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Avalo Therapeutics Inc Highlights
StrengthsRisks
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
Growing
The company is in a growing phase, with the latest annual income totaling USD 441.00K.
Undervalued
The company’s latest PE is -1.06, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 15.54M shares, increasing 1.40% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 804.08K shares of this stock.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
36.111
Target Price
+174.61%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Avalo Therapeutics Inc is 6.70, ranking 225 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 660.69%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.06
Operational Efficiency
2.67
Growth Potential
6.75
Shareholder Returns
7.03
Avalo Therapeutics Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Avalo Therapeutics Inc is 7.46, ranking 119 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.06, which is -233.76% below the recent high of 1.41 and -42.64% above the recent low of -1.51.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 178/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Avalo Therapeutics Inc is 8.80, ranking 48 out of 392 in the Biotechnology & Medical Research industry. The average price target is 35.00, with a high of 48.00 and a low of 24.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
36.111
Target Price
+174.61%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
Avalo Therapeutics Inc
AVTX
11
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Avalo Therapeutics Inc is 1.68, ranking 384 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 16.76 and the support level at 12.33, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
14.664
Sell
MA10
15.036
Sell
MA20
15.531
Sell
MA50
17.099
Sell
MA100
16.012
Sell
MA200
11.163
Buy
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Avalo Therapeutics Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 49.88%, representing a quarter-over-quarter decrease of 1.72%. The largest institutional shareholder is Steven Cohen, holding a total of 1.05M shares, representing 5.81% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BVF Partners L.P.
OrbiMed Advisors, LLC
Nantahala Capital Management, LLC
Affinity Asset Advisors LLC
Caligan Partners, LP
Balyasny Asset Management LP
SilverArc Capital Management, LLC
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Avalo Therapeutics Inc is 3.83, ranking 118 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.90. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.90
VaR
+10.28%
240-Day Maximum Drawdown
+58.88%
240-Day Volatility
+111.52%
Return
Best Daily Return
60 days
+11.68%
120 days
+20.56%
5 years
+357.95%
Worst Daily Return
60 days
-11.68%
120 days
-11.68%
5 years
-88.69%
Sharpe Ratio
60 days
-0.53
120 days
+1.31
5 years
+0.01
Risk Assessment
Maximum Drawdown
240 days
+58.88%
3 years
+99.66%
5 years
+99.97%
Return-to-Drawdown Ratio
240 days
+1.28
3 years
-0.32
5 years
-0.20
Skewness
240 days
+0.77
3 years
+15.40
5 years
+17.64
Volatility
Realised Volatility
240 days
+111.52%
5 years
+170.48%
Standardised True Range
240 days
+6.70%
5 years
+783.95%
Downside Risk-Adjusted Return
120 days
+274.55%
240 days
+274.55%
Maximum Daily Upside Volatility
60 days
+63.68%
Maximum Daily Downside Volatility
60 days
+51.29%
Liquidity
Average Turnover Rate
60 days
+1.75%
120 days
+1.25%
5 years
--
Turnover Deviation
20 days
-99.71%
60 days
-99.82%
120 days
-99.87%
Peer Comparison
Biotechnology & Medical Research
Avalo Therapeutics Inc
AVTX
5.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
